Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Efavirenz (Primary) ; Fosamprenavir (Primary) ; Indinavir (Primary) ; Lopinavir/ritonavir (Primary) ; Nelfinavir (Primary) ; Nevirapine (Primary) ; Ritonavir (Primary) ; Ritonavir (Primary) ; Saquinavir (Primary) ; Tipranavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 06 Dec 2019 New trial record